Patents Assigned to StemCell Technologies Inc.
  • Patent number: 6306575
    Abstract: The present invention relates to an antibody composition which contains antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, and optionally CD45RA, CD38, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and/or antibodies specific for antigens expressed on non-hematopoietic tumor cells. A process is also provided for enriching and recovering human hematopoietic progenitor cells and stem cells in a sample containing human hematopoietic differentiated, progenitor, and stem cells, and optionally tumor cells.
    Type: Grant
    Filed: December 1, 1995
    Date of Patent: October 23, 2001
    Assignee: StemCell Technologies, Inc.
    Inventors: Terry Thomas, Peter Lansdorp
  • Patent number: 6117985
    Abstract: The present invention relates to antibody composition that are useful in preparing enriched cell preparations such as human hematopoietic progenitor cells and stem cells and non-hematopoietic tumor cells. The invention also relates to kits for carrying out the processes and to the cell preparations prepared by the processes.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: September 12, 2000
    Assignee: Stemcell Technologies Inc.
    Inventors: Terry Thomas, Peter Lansdorp
  • Patent number: 5877299
    Abstract: The present invention relates to an antibody composition which contains antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, and optionally CD45RA, CD36, CD56, CD2, CD19, CD66a and/or CD66b. A process is also provided for enriching and recovering human hematopoietic progenitor cells and stem cells in a sample containing human hematopoietic differentiated, progenitor, and stem cells. The process involves reacting the sample with an antibody composition containing antibodies capable of binding to the antigens glycophorin A, CD3, CD24, CD16, and CD14, and optionally CD45RA, CD36, CD56, CD2, CD19, CD66a and/or CD66b under conditions so that cell conjugates are formed between the antibodies and differentiated cells having the antigens glycophorin A, CD3, CD24, CD16, and CD14, and optionally CD45RA, CD36, CD56, CD2, CD19, CD66a and/or CD66b on their surfaces. The cell conjugates are removed and a cell preparation is obtained which is enriched in human hematopoietic progenitor cells and stem cells.
    Type: Grant
    Filed: June 16, 1995
    Date of Patent: March 2, 1999
    Assignee: Stemcell Technologies Inc.
    Inventors: Terry Thomas, Peter Lansdorp